The Financial results for the year ended 31-03-2026 are attached herewith.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hamps Bio Ltd reported standalone revenue of ₹851.65 lakhs for FY26, up 27.7% from ₹666.87 lakhs in FY25, driven by growth in both pharmaceutical trading and freeze-dried products segments. However, the company swung to a loss with standalone loss after tax of ₹61.86 lakhs compared to profit of ₹40.39 lakhs in FY25. Consolidated results (including newly acquired subsidiary HSDL Innovative) showed a larger loss of ₹101.95 lakhs. Operating cash flow was negative at ₹286.32 lakhs, reflecting working capital pressures from expansion. The company completed its IPO proceeds utilization (₹622.20 lakhs) and issued 1:1 bonus shares during the year. The statutory auditor issued an unmodified (clean) opinion on both standalone and consolidated results.
Despite strong revenue growth of nearly 28%, the shift to losses and negative operating cash flow signals near-term pressure on profitability. The ₹286 lakh operating cash outflow and ongoing FMCG expansion investments may weigh on investor sentiment, though clean audit opinion provides assurance on financial reporting integrity.